Amathus Therapeutics Overview
- Year Founded
-
2016
- Status
-
Out of Business
- Employees
-
3
- Latest Deal Type
-
Out of Business
Amathus Therapeutics General Information
Description
Developer of small-molecule therapeutics designed to improve mitochondrial function. The company's therapeutics help in the treatment of rare lysosomal-storage disorders, enabling healthcare professionals to treat neurodegenerative diseases.
Contact Information
Website
www.amathustx.comCorporate Office
- 700 Main Street North
- Cambridge, MA 02139
- United States
Corporate Office
- 700 Main Street North
- Cambridge, MA 02139
- United States
Amathus Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Out of Business | 19-Jul-2025 | Completed | Out of Business | |||
| 4. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 3. Early Stage VC (Series A1) | 25-Mar-2019 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 14-Nov-2018 | $50K | $50K | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | Completed | Generating Revenue |
Amathus Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A1 | ||||||||
| Series A |
Amathus Therapeutics Patents
Amathus Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4121029-A1 | Benzenesulfonamide derivatives as trap1 modulators and uses thereof | Inactive | 20-Mar-2020 | ||
| WO-2021188880-A1 | Benzenesulfonamide derivatives as trap1 modulators and uses thereof | Inactive | 20-Mar-2020 | ||
| EP-4121072-A1 | Cyclic sulfonamide derivatives as trap1 modulators and uses thereof | Inactive | 20-Mar-2020 | ||
| WO-2021188911-A1 | Cyclic sulfonamide derivatives as trap1 modulators and uses thereof | Inactive | 20-Mar-2020 | ||
| EP-4121030-A1 | Pyridinesulfonamide derivatives as trap1 modulators and uses thereof | Inactive | 20-Mar-2020 | C07D413/12 |
Amathus Therapeutics Signals
Amathus Therapeutics FAQs
-
When was Amathus Therapeutics founded?
Amathus Therapeutics was founded in 2016.
-
Where is Amathus Therapeutics headquartered?
Amathus Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Amathus Therapeutics?
Amathus Therapeutics has 3 total employees.
-
What industry is Amathus Therapeutics in?
Amathus Therapeutics’s primary industry is Drug Discovery.
-
Is Amathus Therapeutics a private or public company?
Amathus Therapeutics is a Private company.
-
What is Amathus Therapeutics’s current revenue?
The current revenue for Amathus Therapeutics is .
-
How much funding has Amathus Therapeutics raised over time?
Amathus Therapeutics has raised $16.1M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process